Title
Category
Credits
Event date
Cost
When the Default is Not Enough: An Emergency Medicine Clinician's Guide to Novel Amyloid-Related Imaging Abnormalities in Alzheimer's Disease
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
 
Following a Moving Target: Current and Emerging Strategies for the Prevention and Management of COVID-19 in Patients with Multiple Sclerosis
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionAs our understanding of COVID-19 advances, so does our understanding of its impact on the management of multiple sclerosis (MS). In this activity, originally delivered as a live webcast, Drs.
Pathways to Progress: Outlining Key Steps to Diagnosis and Evolving Therapeutic Approaches in CIDP
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
$0.00
Program DescriptionDespite recent advancements in chronic inflammatory demyelinating polyneuropathy (CIDP), significant challenges persist in its accurate diagnosis and optimal treatment. Throughout this program, Drs. Nicholas J. Silvestri, Christyn Edmundson, and Kelly G. Gwathmey will share their expertise, as they guide you through common electrodiagnostic and management pitfalls, outlining evidence-based approaches and drawing from their clinical experience with this rare disease.
Pay It Forward: Bridging the Gaps Between Payers and Providers to Get the Medication Your Patient Needs When They Need It for Narcolepsy and Idiopathic Hypersomnia
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
$0.00
Program DescriptionPatients with narcolepsy type 1 (NT-1), narcolepsy type 2 (NT-2), and idiopathic hypersomnia (IH) have a diverse range of clinical presentations and therapeutic needs that complicate the process of diagnosis and management. Although significant advancements have been made with the recent approval of several pharmacologic agents specifically indicated for these disorders, the pursuit of insurance authorization for these strategies often leads to obstacles that limit optimal clinical implementation and corresponding patient outcomes.
The Hidden Side of Multiple Sclerosis: Harnessing Key Pathologies to Improve Outcomes Across the Multiple Sclerosis Spectrum
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Attendance
$0.00
Program DescriptionThe understanding of MS pathophysiology has rapidly advanced in recent years, prompting reevaluation of concepts that were once considered understood.
Lost in Transition: Pearls From An Interactive Workshop to Improve the Journey to Adulthood in Spinal Muscular Atrophy
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionHistorically, patients with the most severe forms of spinal muscular atrophy (SMA) were largely unable to survive into adulthood, and those that did often were treated with a palliative approach. However, with the arrival of therapies that can dramatically shift the path of the disease, more and more patients are entering life-long adult care. Unfortunately, as this transition is a new consideration, many clinicians are still learning how to coordinate and manage it appropriately. 
The Path to Least Resistance: The Emerging Role of Noncovalent BTK Inhibitors in CLL/SLL Across Clinical Practice Settings
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
$0.00
Program DescriptionThe advent of covalent Bruton’s tyrosine kinase inhibitors (cBTKi) (e.g., ibrutinib) in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has significantly enhanced long-term outcomes and quality-of-life for patients as the treatment landscape continues to shift away from traditional chemoimmunotherapy approaches. However, many patients eventually develop treatment resistance, driving disease progression and further limiting therapeutic options.
Alzheimer’s Disease Diagnosis Time Outs: A Deep Dive into Challenging Clinical Scenarios for Early Alzheimer's Diagnosis and Treatment
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionThe management of AD is at the beginning of a seismic paradigm shift. Historically, clinical strategy has been tailored to a therapeutic armamentarium that was nonspecific and directed solely at symptom management. This mindset coincides with a variety of outdated and potentially harmful assumptions such as the idea that early diagnosis provides limited clinical value. Now that anti-Aβ antibodies are making their way into the clinic, the entire spectrum of AD care, from diagnosis through therapy, must be re-engineered.